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Renu Virmani, MD*
Gaithersburg, Maryland; and Atlanta, Georgia
Objectives Human coronary bare-metal stents (BMS) and drug-eluting stents (DES) from autopsy cases with implant
duration 30 days were examined for the presence of neointimal atherosclerotic disease.
Background Neointimal atherosclerotic change (neoatherosclerosis) after BMS implantation is rarely reported and usually
occurs beyond 5 years. The incidence of neoatherosclerosis after DES implantation has not been reported.
Methods All available cases from the CVPath stent registry (n  299 autopsies), which includes a total of 406 lesions—
197 BMS, 209 DES (103 sirolimus-eluting stents [SES] and 106 paclitaxel-eluting stents [PES])—with implant
duration 30 days were examined. Neoatherosclerosis was recognized as clusters of lipid-laden foamy macro-
phages within the neointima with or without necrotic core formation.
Results The incidence of neoatherosclerosis was significantly greater in DES lesions (31%) than BMS lesions (16%; p 
0.001). The median stent duration with neoatherosclerosis was shorter in DES than BMS (DES, 420 days [inter-
quartile range [IQR]: 361 to 683 days]; BMS, 2,160 days [IQR: 1,800 to 2,880 days], p  0.001). Unstable le-
sions characterized as thin-cap fibroatheromas or plaque rupture were more frequent in BMS (n  7, 4%) than
in DES (n  3, 1%; p  0.17), with relatively shorter implant durations for DES (1.5  0.4 years) compared to
BMS (6.1  1.5 years). Independent determinants of neoatherosclerosis identified by multiple logistic regression
included younger age (p  0.001), longer implant durations (p  0.001), SES usage (p  0.001), PES usage
(p  0.001), and underlying unstable plaques (p  0.004).
Conclusions Neoatherosclerosis is a frequent finding in DES and occurs earlier than in BMS. Unstable features of neoathero-
sclerosis are identified for both BMS and DES with shorter implant durations for the latter. The development of
neoatherosclerosis may be yet another rare contributing factor to late thrombotic events. (J Am Coll Cardiol
2011;57:1314–22) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.011Percutaneous coronary interventions (PCI) involving stent-
ing are the most widely performed procedures for the
treatment of symptomatic coronary disease (1). Although
first-generation drug-eluting stents (DES), including
sirolimus-eluting stents (SES [Cypher, Cordis Corp., Mi-
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accepted January 5, 2011.ami Lakes, Florida]) and paclitaxel-eluting stents (PES
[Taxus, Boston Scientific, Natick, Massachusetts]), have
radically reduced restenosis (2,3), complications of late stent
thrombosis (LST) and very late stent thrombosis (VLST)
have emerged as an important but small limitation to this
technology.
See page 1323
Both clinical imaging and autopsy studies suggest that the
primary etiology of LST is the lack of complete endotheli-
alization over stent struts. Interrogation of stented coronary
arteries by angioscopy confirms that the incidence of un-
covered struts in patients receiving DES is high, 20% at 2
years (4). However, the cause of LST is considered to be
multifactorial, and other mechanisms in addition to delayed
healing may be important in the pathophysiology of LST.
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March 15, 2011:1314–22 Neoatherosclerosis in BMS and DESAlthough a thrombotic event related to atherosclerosis of
native coronary vessels is a widely accepted cause of acute
coronary syndromes and sudden death (5), there is little
information in reference to lesion morphologies that may
contribute to thrombosis associated with stents. Chen et al. (6)
have reported that a significant number of patients with
bare-metal stents (BMS) and restenosis present with acute
myocardial infarction or unstable angina, raising the question
whether these events might be attributable to plaque rupture
within the neointima. Although we have also reported a case of
sudden coronary death caused by plaque rupture secondary to
atherosclerotic change developing within the neointima of a
BMS (7), this phenomenon is believed to be rare and is
thought to occur with extended implant durations beyond 5
years (8). The incidence of atherosclerosis occurring within
DES and BMS implants at autopsy has not been examined
systematically. The present investigation represents a histo-
pathological study of atherosclerosis occurring within BMS
and DES implants focused on the incidence, character, and
temporal development, in particular as an underlying cause for
acute coronary thrombosis.
Methods
Patients and lesions. All available material from the
CVPath stent registry, which includes 299 consecutive autopsy
cases (142 BMS, 157 DES [81 SES and 76 PES] patients)
with 406 lesions of30 days’ implant duration (197 BMS, 209
DES [103 SES and 106 PES] lesions) was reviewed. Hearts
with multiple stents, overlapping, and consecutively implanted
stents were treated as 1 lesion, whereas stents including a gap
of 5 mm were treated as separate lesions, as previously
described (9). The cause of death was reported as stent-related
eath (thrombosis and restenosis with or without diffuse
oronary artery disease [CAD]), nonstent-related cardiac
eath, and noncardiac death as previously defined (9). All
vailable clinical records were reviewed for the duration of
mplant, risk factors, and mechanism of death.
istologic preparation. Hearts with stented arteries were
xed in 10% neutral buffered formalin, dissected off the
eart, radiographed, and submitted for plastic embedding in
ethylmethacrylate. Coronary arteries were segmented at
- to 3-mm intervals, and histologic sections were cut at 6
m and stained with hematoxylin-eosin and Movat penta-
chrome, as previously described (9).
Pathologic assessment. Acute thrombosis was defined as a
platelet-rich thrombus occupying 30% of the cross-
ectional area of the lumen, and stent restenosis was defined
s 75% cross-sectional area narrowing by neointimal
ormation. The native plaques (outside stent struts) were
ssessed and classified using our modified American Heart
ssociation classification, to include traditional definitions
f pathological intimal thickening, fibroatheroma, thin-cap
broatheroma, and plaque rupture. Fibrotic lesions with or
ithout calcification that did not show macrophage infil-ration were noted separately (5). Atherosclerosis of the Peointima within the stent was
efined as peristrut foamy mac-
ophage clusters with or without
alcification, fibroatheromas,
hin-cap fibroatheromas, and
uptures with thrombosis. In all
ases, there was no communica-
ion of the lesion within the stent
ith the underlying native ath-
rosclerotic plaque.
Immunohistochemistry for the
dentification of macrophages
as carried out in selected cases
sing a CD68 antibody (dilution
:800, Dako, Carpinteria, Cali-
ornia), as previously described
10). The primary antibody was
abeled using an LSAB kit
Dako) and positive staining vi-
ualized by a 3-amino-9ethyl
arbazole (AEC) substrate-
hromogen system with Gill’s
ematoxylin as a counterstain.
The data were analyzed on the basis of lesions and not by
atients, as often the duration of multiple stents varies as
atients undergo repeat PCI dictated by the onset of
ymptoms. The development of atherosclerotic change by
uration of stent implantation was also assessed in addition
o the regional placement of the stent.
tatistical analysis. Continuous variables with normal dis-
ribution were expressed as mean  SD. Variables with
on-normal distribution were expressed as median (inter-
uartile range [IQR]). Comparisons of continuous variables
ith normal distribution were tested by Student t test. A
ilcoxon rank-sum test was used for comparisons of
on-normally distributed continuous variables. Categorical
ariables were compared using the chi-square test. Normal-
ty of distribution was tested with the Wilk-Shapiro test.
ultiple logistic generalized estimating equations (GEE)
odeling (9) was performed to identify the determinants of
tent neoatherosclerosis, in which age, sex, and significant
ariables (p  0.05) among lesion characteristics (the
umber of stents, stent duration, indication of stent implan-
ation, lesion location, stent length, overlapping stents,
nderlying plaque morphology, and stent type) in univariate
nalysis were entered as independent variables. The GEE
odeling was necessary because of the clustered nature of
1 stented lesions in some cases, resulting in unknown
orrelations among measurements within lesion clusters. A
alue of p  0.05 was considered statistically significant.
esults
atient characteristics. Age, sex, and coronary risk factors
ere similar for patients receiving BMS or DES (Table 1).
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
GEE  generalized
estimating equations
IQR  interquartile range
LST  late stent
thrombosis
OR  odds ratio
PCI  percutaneous
coronary interventions
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
VLST  very late stent
thrombosisatients receiving BMS had a higher prevalence of prior
t and th
y diseas
1316 Nakazawa et al. JACC Vol. 57, No. 11, 2011
Neoatherosclerosis in BMS and DES March 15, 2011:1314–22history of myocardial infarction (p  0.009) and coronary
artery bypass grafts (p  0.008) than patients receiving
DES. Conversely, stent-related deaths from thrombosis
were significantly more frequent for DES than BMS (20%
vs. 4%, p 0.001). Whereas in-stent restenosis as a cause of
death was more frequent among BMS patients than DES
patients (BMS, n  40 [28%]; and DES, n  11 [7%], p 
Patient CharacteristicsTable 1 Patient Characteristics
BMS
(n  142)
All (SES  P
(n  157
Age, yrs 62 14 60 12
Male 105 (74) 117 (7
Hypertension 67/94 (71) 90/114 (7
Diabetes mellitus 41/94 (44) 35/115 (3
Hyperlipidemia 50/94 (53) 73/114 (6
Prior myocardial infarction 85/128 (66) 66/133 (5
Prior CABG 32/139 (23) 18/146 (1
Number of stents per patient 1.4 1.0 1.6 1.
Cause of death
Stent related
Thrombosis 5* (4) 32† (2
Restenosis without diffuse CAD 19 (13) 5 (3
Diffuse CAD with restenosis 20 (14) 4 (3
Nonstent-related cardiac 46 (32) 60 (3
Noncardiac 46 (33) 46 (2
Unknown 6 (4) 10 (6
Values are expressed as means SD or n (%). *Among 5 patients with thrombosis in the BMS gro
hrombosis in the DES group, 1 patient had neointimal plaque rupture, 2 patients had restenosis,
BMS  bare-metal stent(s); CABG  coronary artery bypass graft surgery; CAD  coronary arter
Lesion CharacteristicsTable 2 Lesion Characteristics
BMS
(197 Lesions)
All (SES  PES
(209 Lesions)
Stent duration, days 721 (271–1,801) 361 (172–540
Indication for stent implantation
Stable angina pectoris 150 (76) 150 (72)
Unstable angina pectoris/AMI 47 (24) 59 (28)
Lesion location
Left main coronary artery 4 (2) 6 (3)
Left anterior descending artery 73 (37) 87 (42)
Left circumflex artery 45 (23) 51 (24)
Right coronary artery 75 (38) 65 (31)
Proximal lesion 77/161 (48) 102/202 (51)
Mid/distal lesion 84/161 (52) 100/202 (49)
Stent length, mm 16.0 (12.0–24.0) 22.0 (15.5–30.0
Overlapping stents 36 (18) 63 (30)
Underlying plaque morphology
Ruptured plaque/TCFA 26 (13) 49 (23)
Fibroatheroma 86 (44) 104 (50)
Fibrocalcific 29 (15) 16 (7)
Pathologic intimal thickening 47 (24) 20 (10)
Others* 9 (4) 20 (10)Values are expressed as median (interquartile range) or n (%). *Includes underlying restenotic lesion, cal
AMI  acute myocardial infarction; TCFA  thin-cap fibroatheroma; other abbreviations as in Table 1.0.001), the incidences of nonstent-related death and non-
cardiac death were similar between groups.
Lesion characteristics. The median stent implant duration
was shorter in lesions treated with DES versus BMS (DES,
median 361 days [IQR: 172 to 540 days], BMS, 721 days
[IQR: 271 to 1,801 days]; p  0.001) (Table 2). The
shortest stent duration was 35 days for both SES and PES,
DES
p Value
BMS vs. DES (SES  PES)
SES
(n  81)
PES
(n  76)
60 12 59 12 0.143
59 (73) 58 (76) 0.909
41/56 (73) 49/58 (84) 0.215
14/57 (25) 21/58 (36) 0.060
34/56 (61) 39/58 (67) 0.140
31/67 (46) 35/66 (53) 0.009
10/76 (13) 8/70 (11) 0.008
1.6 1.1 1.7 1.1 0.062
14 (17) 18 (24)  0.001
2 (2) 3 (4) 0.001
3 (4) 1 (1)  0.001
32 (40) 28 (37) 0.293
25 (31) 21 (28) 0.563
5 (6) 5 (7) 0.411
tients had neointimal plaque rupture and 1 patient had restenosis only. †Among 32 patients with
e rest had uncovered struts from varying etiologies.
e; DES  drug-eluting stent(s); PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).
DES
p Value
BMS vs. DES (SES  PES)
SES
(103 Lesions)
PES
(106 Lesions)
361 (180–541) 270 (149–473)  0.001
72 (70) 78 (74) 0.316
31 (30) 28 (26)
2 (2) 4 (4) 0.501
41 (40) 46 (43)
24 (23) 27 (26)
36 (35) 29 (27)
45/98 (46) 57/104 (55) 0.613
53/98 (54) 47/104 (45)
21.0 (15.0–30.0) 22.0 (15.8–30.3)  0.001
30 (29) 33 (31) 0.005
28 (27) 21 (20) 0.008
44 (43) 60 (57) 0.261
8 (8) 8 (7) 0.023
13 (12) 7 (7)  0.001
10 (10) 10 (9) 0.051ES)
)
5)
9)
0)
4)
0)
2)
1
0)
)
)
8)
9)
)
up, 4 pa)
)
)cified nodule, and dissection.
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March 15, 2011:1314–22 Neoatherosclerosis in BMS and DESand 31 days for BMS, whereas the longest stent duration
was 1,800 days for SES, 1,814 days for PES, and 7,201 days
for BMS. Indications for stent implantation and lesion
location were comparable between groups. Stent lengths
were significantly longer in DES (22.0 mm [IQR: 15.5 to
30.0 mm]) than in BMS (16.0 mm [IQR: 12.0 to 24.0 mm];
p  0.001). The prevalence of overlapping stents was also
significantly higher in DES (30%, vs. BMS 18%; p 
0.005). Notably, the underlying plaque morphology was
different, with unstable lesions (i.e., ruptured plaques and
thin-cap fibroatheroma) more commonly found in DES as
compared with BMS (p  0.008). However, fibrocalcific
and pathologic intimal thickening were significantly more
frequent in BMS than DES (p  0.023 and p  0.001,
respectively).
Figure 1 Representative Images of Various Stages of Newly Fo
Atherosclerotic Changes Within Neointima After Sten
(A) Foamy macrophage clusters in the peristrut region of sirolimus-eluting stents (
macrophage-rich lesion and early necrotic core formation in SES of 13 months’ du
foamy macrophages, and early calcification (arrows) in SES at 13 months. (D) Pe
terol cleft in SES at 17 months. (E) Fibroatheroma with calcification in the necroti
SES of 7 months’ duration. (G and H) A low-power magnification image (H) of a se
atheroma. Note macrophage infiltration and a discontinuous thin fibrous cap in a h
plaque rupture with an acute thrombus that has totally occluded the lumen in BMS
discontinuous thin-cap with occlusive luminal thrombus.Incidence of neoatherosclerosis. Representative images of
newly formed atherosclerotic changes within the neointima
in various stents are shown in Figure 1. Notably, 85% (177
lesions) DES were implanted for 2 years or less with no
lesions extending beyond 6 years, while 45% (88 lesions)
BMS were implanted for 2 years or less and 17% (33 lesions)
had durations of 6 years (Table 3). The incidence of any
neoatherosclerosis was greater in DES (n  64, 31%) than
BMS (n  31, 16%) lesions (p  0.001). Nearly one-half
the DES lesions with neoatherosclerosis (31 of 64 lesions,
48%) contained peristrut foamy macrophage clusters, and
the other half showed fibroatheromas. A significant tempo-
ral relationship was found among BMS and DES; athero-
sclerotic change occurred in significantly shorter implant
durations for DES than for BMS (DES, 420 days [IQR:
lantation
mplanted for 13 months antemortem is seen. (B) Fibroatheroma with foamy
(C) Fibroatheroma with peristrut early necrotic core, cholesterol clefts, surface
late necrotic core in the neointima characterized by large aggregate of choles-
in SES of 10 months’ duration. (F) A peristrut calcification (arrows) with fibrin in
narrowed bare-metal stent (BMS) implanted 61 months with a thin-cap fibro-
wer magnification image (G). (I) A low-power magnification image shows a
nted for 61 months antemortem. (J) A high-power magnification image shows armed
t Imp
SES) i
ration.
ristrut
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Neoatherosclerosis in BMS and DES March 15, 2011:1314–22361 to 683 days]; BMS, 2,160 days [IQR: 1,800 to 2,880
days]; p  0.001) (Table 3). The earliest implant duration
howing early atherosclerotic change characterized by foamy
acrophage clusters was observed at 70 days for PES and
20 days for SES, whereas its occurrence in BMS was found
uch later, at 900 days. Similarly, the earliest implant
urations for lesions with necrotic cores were relatively short
n DES: at 270 days and 360 days for SES and PES,
espectively, whereas the earliest duration for necrotic core
ormation in BMS was longer, 900 days. Representative
mages of fibroatheroma with necrotic core from a PES
mplant of 14 months’ duration is illustrated in Figures 2A,
2B, and 2C. The cumulative incidence of any neoathero-
sclerotic change relative to implant duration is shown in
Figure 3, and is significantly higher in DES as compared
with BMS. Notably, the incidence of neoatherosclerosis in
BMS does not catch up to DES despite the longer durations
of stent implantation beyond 6 years.
The incidence of neoatherosclerosis was also evaluated
based on the implant duration (Table 3). For those implants
of 2 years, the DES group had a greater incidence of any
neoatherosclerosis (DES 29% vs. BMS 0%, p  0.001),
Incidence of Neoatherosclerosis Stratified by Duration of ImplantTable 3 Incidence of Neoatherosclerosis Stratified by Duration
BMS
(197 Lesions)
All (SE
(209
Duration with any neoatherosclerosis, days 2,160 (1,800–2,880) 420 (
Incidence of any neoatherosclerosis
2 yrs 0/88 (0) 51/1
2 yrs, 6 yrs 17/76 (22) 13/
6 yrs 14/33 (42)
All 31/197 (16) 64/2
Incidence of foamy macrophage clusters
2 yrs 0/88 (0) 25/1
2 yrs, 6 yrs 2/76 (3) 6/
6 yrs 3/33 (9)
All 5/197 (3) 31/2
Incidence of fibroatheromas
2 yrs 0/88 (0) 23/1
2 yrs, 6 yrs 11/76 (15) 7/
6 yrs 8/33 (24)
All 19/197 (10) 30/2
Incidence of TCFA/plaque rupture
2 yrs 0/88 (0) 3/1
2 yrs, 6 yrs 4/76 (5) 0/
6 yrs 3/33 (9)
All 7/197 (4) 3/2
Calcified neointima 9 (5)
Location of neoatherosclerosis
Proximal lesion 21/77 (27) 34/1
Mid/distal lesion 10/84 (12) 30/1
Values are expressed as median (interquartile range) or n (%). *p  0.021 versus SES group. †p
therosclerotic change in proximal lesion was higher than that in mid/distal lesion in the BMS gr
Abbreviations as in Tables 1 and 2.which was represented by a greater incidence of foamymacrophage clusters (DES 14% vs. BMS 0%, p  0.001) as
well as fibroatheromas (DES 13% vs. BMS 0%, p  0.001).
For durations between 2 years and 6 years, the DES group
still expressed a higher incidence of neoatherosclerosis
(DES 41% vs. BMS 22%, p  0.053) (Table 3). The
incidence of any neoatherosclerotic change was greater in
SES than in PES for implant durations of 2 years or less
(SES 37% vs. PES 21%, p  0.021), although differences
did not remain with stents implanted for 2 to 6 years (SES
44% vs. PES 38%, p  0.719).
In regard to the location of the stent and the development
of atherosclerosis, the incidence of atherosclerotic change in
proximal lesions was significantly higher than those in
mid/distal lesions in BMS (27% vs. 12%, respectively; p 
0.014); however, this difference was not seen in DES (33%
vs. 30%, p  0.611) (Table 3).
More advanced lesions—unstable plaque, namely, thin-
cap fibroatheroma and ruptured plaques with thrombosis
(Figs. 2D to 2I)—were seen for both BMS (n  7, 4%) and
DES (n  3, 1%), where the majority of BMS were 5
years (average implant duration 6.1 1.5 years) whereas for
DES, unstable neoatherosclerotic lesions were identified
plant
DES
p Value
BMS vs. DES (SES  PES)
ES)
ns)
SES
(103 Lesions)
PES
(106 Lesions)
83) 450 (361–660) 383 (270–721)  0.001
) 32/87 (37) 19/90 (21)*  0.001
) 7/16 (44) 6/16 (38) 0.053
— — —
) 39/103 (38) 25/106 (24)†  0.001
) 10/87 (12) 15/90 (17)  0.001
) 4/16 (25) 2/16 (13) 0.004
— — —
) 14/103 (14) 17/106 (16)  0.001
) 19/87 (22) 4/90 (4)‡  0.001
) 3/16 (19) 4/16 (25) 0.346
— — —
) 22/103 (21) 8/106 (8)§ 0.145
3/87 (4) 0/90 (0) 0.219
0/16 (0) 0/16 (0) 0.186
— — —
3/103 (3) 0/106 (0) 0.169
7 (7) 4 (4) 0.747
) 19/45 (42) 15/57 (26) 0.384
) 20/53 (37) 10/47 (21) 0.003
5 versus SES group. ‡p  0.001 versus SES group. §p  0.004 versus SES group. Incidence of
% vs. 12%, p  0.014), but not in the DES group (33% vs. 30%, p  0.611).of Im
S  P
Lesio
361–6
77 (29
32 (41
—
09 (31
77 (14
32 (19
—
09 (15
77 (13
32 (22
—
09 (14
77 (2)
32 (0)
—
09 (1)
11 (5)
02 (33
00 (30
 0.02
oup (27with devices implanted 2 years (1.1, 1.4, and 1.9 years).
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March 15, 2011:1314–22 Neoatherosclerosis in BMS and DESDetails of the 10 patients (7 BMS and 3 DES) with
thin-cap fibroatheroma or plaque rupture within the in-
stent neointima are provided in the visual Table 4.
The incidence of neoatherosclerosis did not differ be-
tween patients with stent-related death and patients with
nonstent-related death, both in BMS (18% vs. 20%, p 
0.848) and in DES (27% vs. 42%, p  0.099). In patients
with stent-related death, the incidence of neoatherosclerosis
was comparable between BMS and DES (18% vs. 27%, p
0.339), whereas in patients with nonstent-related death,
DES had a higher incidence of neoatherosclerosis than
BMS (42% vs. 20%, p  0.001).
A multiple logistic GEE modeling identified younger age
(odds ratio [OR]: 0.963, 95% confidence interval [CI]:
0.942 to 0.983; p  0.001), longer implant duration (OR:
1.028, 95% CI: 1.017 to 1.041; p 0.001), SES usage (OR:
.534, 95% CI: 3.387 to 12.591; p  0.001), PES usage
Figure 2 Representative Cases Showing Atherosclerotic Chang
(A to C) Histologic sections from a 65-year-old woman with a PES implanted in th
A low-power image shows a patent lumen with moderate neointimal growth; (B) fo
at high magnification. (C) Same section as (B) showing CD68-positive macrophag
old man (Patient #10 in Table 4) with SES implanted for 23 months, who died of
3-mm apart. (E) Note thin-cap fibroatheroma with fibrous cap disruption (arrows),
and in the underlying necrotic core (arrows). (G) Histologic section from a 47-year
occlusive thrombus (Th) in the lumen and ruptured plaque (boxed area), which is
as well as at the ruptured cap. (I) Note large number of CD68-positive macrophagOR: 3.200, 95% CI: 1.584 to 6.469; p  0.001), and tnderlying unstable plaque (OR: 2.387, 95% CI: 1.326 to
.302; p  0.004) as independent risk factors for neoath-
rosclerosis (Table 5).
iscussion
he present study suggests that in-stent neoatherosclerosis
ccurs in both BMS and DES; however, for DES implants,
t is observed more frequently and at an earlier time point
median 420 days) as compared with BMS (median 2,160
ays). For stent-related deaths, in-stent neoatherosclerosis
ncidence was similar for BMS and DES (18% vs. 20%).
owever, for nonstent-related death, the incidence of
eoatherosclerosis was more frequent for DES than BMS
42% vs. 20%, p  0.001). Moreover, neoatherosclerosis in
ES shows unstable characteristics by 2 years after implant,
hereas similar features in BMS occur at relatively later
er PES, SES, and BMS Implantation
ircumflex artery 14 months antemortem, who died of traumatic brain injury. (A)
acrophage infiltration and necrotic core formation with cholesterol clefts is seen
he neointima (* indicates stent strut). (D) Histological sections from a 59-year-
hrombosis. The thrombus (Th) was more apparent in the distal section taken
oxed area in D. (F) The CD68-positive macrophages are seen in the fibrous cap
an (Patient #8 in Table 4) who had a BMS implanted 8 years before death. Note
at higher magnification in H with large number of macrophages within the lumen
the site of rupture. Abbreviations as in Figure 1.e Aft
e left c
amy m
es in t
stent t
from b
-old m
shown
es atimes (average implant duration 6 years). These observa-
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Neoatherosclerosis in BMS and DES March 15, 2011:1314–22tions raise the question whether neoatherosclerosis seen
within DES as well as BMS at follow-up may in part be
responsible for some late thrombotic events. The implica-
tions of current findings may be of practical importance as
the usage of DES implants continues to increase worldwide.
The occurrence of uncovered struts complicated by a dys-
functional endothelium remains the primary cause of LST
in DES; nevertheless, the present study adds another risk
factor, namely, in-stent plaque rupture, although a rare
event.
Although the underlying processes responsible for the
development of neoatherosclerosis after stent implantation
are likely multifactorial, we hypothesize that it may involve
the inability to maintain a fully functional endothelialized
luminal surface within the stented segment (11). The
endothelium normally provides an efficient barrier against
the excessive uptake of circulating lipid, and that may no
longer be true in the in-stent regions of DES and BMS
(12). In the present study, BMS exhibited greater trends for
neoatherosclerotic changes occurring in the more proximal
than distal lesions relative to DES, thus indicating divergent
mechanisms by which neoatherosclerosis attributed to DES
may be more related to incompetent and incomplete endothe-
lialization as opposed to shear stress for BMS. These findings
in the BMS may be more akin to the development of
atherosclerosis in native coronary arteries, and is most promi-
nent in the proximal regions of the coronary arteries (13).
Recently, chronic endoplasmic reticular stress in endo-
thelial cells at athero-susceptible sites with arterial flow
disturbances has been linked to inflammation (14). Shear-
induced changes in endothelial phenotype (collectively
known as mechanotransduction) may promote the expres-
sion of transmembrane proteins, like integrins and platelet
endothelial cell adhesion molecule-1, which further allow
Figure 3 Cumulative Incidence of Atherosclerotic Change With
Time After Implantation of BMS Versus SES and PES
Both SES (dark blue bars) and PES (medium blue bars) show earlier onset of
neoatherosclerosis and a higher incidence of lesion formation as compared
with BMS (light blue bars). No drug-eluting stents were available beyond 6
years. Abbreviations as in Figure 1.inflammatory cell attachment and migration to subendothe-lial spaces (13). Changes in endothelial cell permeability
could presumably allow greater amounts of lipoproteins to
enter the subendothelial space, with an affinity for matrix
proteins, in particular proteoglycans that promote their
retention (15).
The relatively faster development of neoatherosclerosis in
DES than in BMS is probably related to drug effects, which
are also responsible for incomplete endothelialization. Pre-
vious animal studies of DES (11) suggest that the regener-
ating endothelial lining could be incompetent, and therefore
may result in endothelial cells activation, which leads to
monocyte adherence with subsequent subendothelial migra-
tion. Incomplete (delayed) endothelial regrowth and recov-
ery observed with SES or PES that may contribute to
atherogenesis is characterized by poor cell-to-cell contacts
identified by decreased expression of platelet endothelial cell
adhesion molecule-1 and antithrombotic mediators such as
thrombomodulin (11).
Experimental evidence suggests that neoatherosclerosis
within stents can be associated with delayed arterial healing
compounded by lethal injury to smooth muscle cells and
endothelial cells. We have reported that a 32P -emitting
tent implanted, with activities ranging from 6 Ci to 48
Ci, showed focal evidence of atherosclerotic change in
normal arteries of New Zealand White rabbits examined at
6 and 12 months (16). Considering it is well known that
atherosclerosis does not develop in normal arteries of the
rabbit in the absence of hypercholesterolemia, these results
suggest that the atherogenic process is inherent to process
occurring within the stent itself.
In humans, 2 pathology studies have reported neoathero-
sclerotic change occurring in vein graft and in native
coronary arteries with foam cell infiltration after BMS
implants (17,18). Previous clinical studies have also sug-
gested endothelial dysfunction after SES implantation by
showing impaired vasomotor function in the adjacent seg-
ment of stents (19), although the precise mechanism for the
endothelial dysfunction in the stented segment in humans
remains unknown.
Clinical relevance. Coronary SES implants in 57 patients
recently interrogated by angioscopy showed a 35% increase
in the maximum yellow color of the neointima within 10
months of follow-up (20). Even among lesions that did not
express yellow plaque at baseline, yellow color was detected
in 95% of SES implants, suggesting a neoatherosclerotic
change in response to the stent.
A retrospective analysis of 4,503 patients with at least 1
BMS implant, reported by Doyle et al. (21), showed that
the incidence of stent thrombosis was 0.8% at 1 year and 2%
at 10 years, which is lower than reported for DES (SES and
PES), 2.9% at 3 years, involving an all-comer registry of
8,146 patients (22). In contrast, a meta-analysis of 18,023
patients reported by Stettler et al. (23) revealed that mor-
tality risks were similar between BMS and DES (SES and
PES), although several trials included in the meta-analysis
evaluated only cardiac and not all-cause mortality. The
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March 15, 2011:1314–22 Neoatherosclerosis in BMS and DESPatients With TCFA or Plaque Rupture Within Neointima After Stent ImplantationTable 4 Patients With TCFA or Plaque Rupture Within Neointima After Stent Implantation
Patient #
Age, yrs
Sex Stent Type Location
No. of
Stents
Stent
Length,
mm
Implant
Indication
Implant
Duration,
Months
Cause of
Death
Representative
Images
Thin-cap fibroatheroma
1 58 M BMS (NIR) LAD Proximal 1 18 SAP 61 Noncardiac
2 63 M BMS (Multi-Link) RCA mid 1 18 SAP 98 Nonstent-related
cardiac
3 73 M BMS (Bx Velocity) RI Proximal 1 16 SAP 50 Noncardiac
4 40 F DES (SES) RCA proximal 1 23 AMI 17 Stent-related
(thrombosis)
5 67 M DES (SES) RCA proximal 1 13 SAP 13 Nonstent-related
cardiac
Plaque rupture
6 43 M BMS (Mini-Crown) LAD proximal 1 14 SAP 84 Stent-related
(thrombosis)
7 87 F BMS (2 AVE) RCA proximal 2 60 SAP 61 Stent-related
(thrombosis)
8 47 M BMS (3 Gianturco-Roubin II) RCA proximal 3 90 SAP 96 Stent-related
(thrombosis)
9 43 M BMS (5 Multi-Link Zeta) RCA proximal/
distal
5 70 SAP 61 Stent-related
(thrombosis)
10 59 M DES (SES) RCA distal 1 23 AMI 23 Stent-related
(thrombosis)LAD  left anterior descending artery; RCA  right coronary artery; RI  ramus intermedius; SAP  stable angina pectoris; other abbreviations as in Tables 1 and 2.
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gioplasty Registry), reported by Lagerqvist et al. (24),
involved 73,798 stents from 42,150 patients with DES and
BMS and showed a biphasic incidence of LST, with higher
rates in the first year in BMS followed by a higher rate in
DES from 1 to 3 years, for unadjusted cumulative proba-
bility of acute occlusion. However, after adjustment for
background and procedure characteristics, no differences
were observed at 3 years. As compared with large clinical
trials, our study shows apparently higher rates of stent
thrombosis, probably because the population may be biased
toward patients dying of DES complications (all comers
without adjustment). In addition, our population is nonran-
domized, and unknown confounders could exist even after
adjustment by multivariate GEE modeling. Despite these
shortcomings, to our knowledge, the present study repre-
sents the first report demonstrating the incidence and type
of neoatherosclerosis within DES and BMS from a large
series of stents implanted in native human coronary arteries.
Because only histologic studies can provide sufficient detail
to accurately characterize neoatherosclerosis within stents,
our results offer important insights into late cardiac events
attributed to stents.
Conclusions
The current pathology study suggests that neoatherosclero-
sis is a frequent finding in DES, and occurs significantly
earlier in DES as compared with BMS; however, compli-
cations are more frequent for BMS than for DES and are
likely due to longer implant duration. These observations
suggest that neoatherosclerosis could be accelerated in DES,
and in rare cases, contribute to very late thrombotic events
in both BMS and DES.
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